FEMOGEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FEMOGEN (FEMOGEN).
Femogen is a combination of estradiol (an estrogen) and norethindrone acetate (a progestin). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and promoting proliferation of the endometrium. Norethindrone acetate suppresses gonadotropin secretion and inhibits endometrial proliferation, reducing the risk of endometrial hyperplasia associated with estrogen therapy.
| Metabolism | Estradiol is metabolized primarily in the liver via conversion to estrone and estriol, and undergoes hydroxylation and conjugation (glucuronidation and sulfation). Norethindrone acetate is hydrolyzed to norethindrone, which is metabolized via reduction, hydroxylation, and conjugation (primarily glucuronidation). Enzymes involved include CYP3A4 for norethindrone. |
| Excretion | Renal: 60-70% as glucuronide conjugates; Biliary/Fecal: 30-40% as metabolites; <1% unchanged. |
| Half-life | Terminal half-life: 13.2 ± 2.3 hours; clinically, steady-state reached after 3-5 days. |
| Protein binding | 97-99% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | 3.4 ± 0.8 L/kg; distributes into adipose tissue and reproductive organs. |
| Bioavailability | Oral: 5-10% (extensive first-pass metabolism). |
| Onset of Action | Oral: 0.5-1 hour; Intramuscular: 15-30 minutes; Subcutaneous: 10-20 minutes. |
| Duration of Action | Oral: 8-12 hours; Depot intramuscular: 2-3 weeks; Subcutaneous implant: 3-6 months. |
1 mg orally once daily for 21 days, followed by 7 days off; for HRT, 1 mg orally once daily continuously.
| Dosage form | TABLET |
| Renal impairment | No adjustment required; estradiol is not significantly renally cleared. |
| Liver impairment | Contraindicated in severe hepatic disease; for mild-moderate impairment (Child-Pugh A or B), reduce dose by 50% and monitor liver function. |
| Pediatric use | Not FDA-approved for use in children; no established dosing. |
| Geriatric use | Use lowest effective dose for shortest duration; increased risk of thromboembolism and malignancy; monitor closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FEMOGEN (FEMOGEN).
| Breastfeeding | FEMOGEN is not recommended during breastfeeding. Small amounts of estrogens and progestins are excreted in breast milk; M/P ratio is not established. Potential adverse effects include reduced milk production and altered breast milk composition. Use only if clearly needed and consider alternative contraception. |
| Teratogenic Risk | FEMOGEN is contraindicated in pregnancy. First trimester: Estrogens and progestins have been associated with congenital anomalies, including cardiovascular and limb defects, and an increased risk of vaginal adenosis and clear-cell adenocarcinoma in female offspring. Second and third trimesters: Use may cause fetal harm, including urogenital abnormalities and feminization of male fetuses. |
■ FDA Black Box Warning
Estrogens and progestins should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) substudy reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) receiving 0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate. The Women's Health Initiative Memory Study (WHIMS) reported an increased risk of probable dementia in women ≥65 years of age taking estrogen plus progestin.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active or history of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism)","Active or history of arterial thromboembolism (e.g., stroke, myocardial infarction)","Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency)","Known hepatic impairment or disease","Known or suspected pregnancy","Hypersensitivity to any component of the product"]
| Precautions | ["Risk of cardiovascular disorders (myocardial infarction, stroke, venous thromboembolism)","Risk of breast cancer and endometrial cancer","Risk of dementia in women ≥65 years","Gallbladder disease","Hypertriglyceridemia","Fluid retention","Hepatic hemangioma enlargement","Exacerbation of endometriosis","Hypocalcemia in hypoparathyroidism","Ocular abnormalities (retinal thrombosis)"] |
Loading safety data…
| Fetal Monitoring | Monitor for pregnancy status prior to initiation and periodically. If pregnancy occurs, discontinue immediately. Monitor for signs of thrombosis, hypertension, glucose intolerance, and lipid abnormalities. In pregnant women inadvertently exposed, consider fetal ultrasound to assess for anomalies. |
| Fertility Effects | FEMOGEN suppresses ovulation through estrogen and progestin activity. Upon discontinuation, return to fertility may be delayed but is typically transient. Long-term use does not impair permanent fertility. |